This excerpt taken from the ELN 20-F filed Mar 30, 2006.
HOSPITAL BUSINESS AND PRODUCTS
Severe bacterial infections remain a major medical concern, even more so with the rise in resistance and fewer available therapies. We market two products that treat severe bacterial infections, each designed to address specific medical needs within the hospital market. Distinct from the community market, the hospital market is highly specialized and often relies on a team of healthcare professionals that influences the decision-making process. We are committed to meeting the needs of the infectious disease and critical care community within the hospital market.
The Hospital Business actively maintains relationships with 1,035 hospitals throughout the United States, each characterized by unique and complex decision-making processes. Approximately 550 of these are leading academic-teaching institutions. Our hospital sales force maintains key relationships with doctors and other healthcare professionals in the areas of infectious disease, critical care, pulmonary, emergency and pharmacy; and frequently interacts with oncologists.
We licensed the U.S. marketing rights to Maxipime from Bristol-Myers Squibb Company (Bristol-Myers) in January 1999. Maxipime is a fourth-generation injectable cephalosporin antibiotic used to treat patients with serious and/or life-threatening infections. Pulmonologists, infectious disease specialists, emergency medicine specialists, surgeons, internal medicine physicians, hematologists and oncologists prescribe Maxipime for patients with severe infections requiring hospitalization, such as pneumonia, urinary tract infection and febrile neutropenia. Attributes of Maxipime are its broad spectrum of activity, including activity against many pathogens resistant to other antibiotics, ease of use and favorable pharmaco-economic profile. Revenue from sales of Maxipime amounted to $140.3 million for 2005. The basic U.S. patent on Maxipime expires in March 2007. However, two other U.S. patents covering Maxipime formulations may provide protection until February 2008.
We licensed the U.S. marketing rights to this injectable antibiotic from Bristol-Myers in January 1999. Azactam is a monobactam and is principally used by surgeons, infectious disease specialists and internal medicine physicians to treat pneumonia, post-surgical infections and septicemia. Revenue from sales of Azactam totalled $57.7 million for 2005. The basic U.S. patent on Azactam expired in October 2005. To date, no generic Azactam product has been approved. However, we expect that generic competition to Azactam will emerge in 2006.
Please refer to Item 5.A Operating Results for additional information concerning our revenue by category for 2005, 2004 and 2003.